Genesis Molecular AI (formerly Genesis Therapeutics)

Research on the record

• 2026-06-03Genesis says its Pearl system, given only an unbound protein structure, posed 78% of 802 ligands within its best 25 tries in OpenBind's EV-A71 benchmark, above every co-folding model OpenBind testedLevel 2 · Computed
• 2025-10-28Genesis says its Pearl model places drug molecules in proteins about 14% better than AlphaFold 3Level 2 · Computed

Graded by how far the evidence went, not how good the result is. See the methodology.

People

Only people the AI4S.fyi record has named: in a round, a timeline entry, commentary, an interview or a sourced role. Not the full team.

Funding rounds tracked

• 2023-08-21Series B · $200MconfirmedLed by Andreessen Horowitz, unnamed life-sciences investor · With Fidelity, BlackRock, NVentures (NVIDIA), T. Rowe Price, Rock Springs Capital, Menlo Ventures, Radical VenturesStated use: take wholly owned programs into the clinic
• 2020-12-02Series A · $52MconfirmedLed by Rock Springs Capital · With T. Rowe Price, Andreessen Horowitz, Menlo Ventures, Radical Ventures, Felicis Ventures, Jazz Venture Partners, Harpoon Ventures, Ulu Ventures, Mark Leslie, Jeffrey Rothschild, Propagator Ventures, Open Field CapitalStated use: grow the team, AI technology and pipeline

Each round links to its line on the funding record, with its source.

Also in Drug discovery on the funding board

The other companies the funding board files under the same field, latest round first. A list of what the record tracks, not a ranking or a market map.

• 2026-10-29ALLOXSeed · US$10.5M (€9.4M)Measures the effects of thousands of protein mutations at once to map allosteric and other regulatory sites, and builds AI models on that data to find drug-binding spots on hard targets such as protein-protein interactions and transcription factors, for its own small molecules.
• 2026-10-27Atlas BioSeed · $10MRuns in silico clinical trials, starting in immunology: a foundation model trained on about 2 million RNA readouts from human tissue predicts each virtual patient's response to several treatments and diseases, to help drug developers choose what to take into Phase II.
• 2026-10-23Pathos AISeries E · $237MLicenses clinical-stage drugs from other companies and develops them itself, using an agent platform (Foundry, earlier PathOS) trained on patient records to choose assets, pick the patients most likely to respond and adjust trials as they run. Its pipeline is in cancer: prostate cancer, multiple myeloma, lung and breast cancer and TROP2/HER3-expressing solid tumours; in October 2026 it began work in Alzheimer's disease with Bristol Myers Squibb and Tempus.
• 2026-10-23Zhichong PharmaSeries A1 · tens of millions of yuanDevelops new drugs for pets with generative AI, using its own small-molecule and large-molecule design engines (ChemoFetch and OmniFetch), and argues that testing in the target animal closes the loop from design to evidence faster than human drug development can; its programmes are in anti-infectives, chronic disease and ageing.
• 2026-10-14Gaowei YiyaoPre-A · undisclosed; PEdaily says the company has raised several hundred million yuan so far this yearMines protein-interaction and other high-dimensional biology data with its own models to find drug targets others treat as undruggable, then runs its own small-molecule and antibody programmes. Its GROOVY platform found the target behind GW-01, a Notch-pathway inhibitor now in Phase I; ACUMEN maps pairs of neighbouring cell-surface proteins for bispecifics and NEXUS looks for tumour neoantigens.
• 2026-10-14Iambic TherapeuticsIPO · $150MDesigns small-molecule cancer drugs with AI structure-prediction models (NeuralPLexer) linked to an automated chemistry and biology lab.

All 37 in this field →